Antiplatelet therapy

Antiplatelet therapy has been studied in 25 papers since 2016: 1 trial and 13 observational studies in people, 10 reviews; 15 in the past year. The newest paper, Nov 2, 2026: “Adverse Clinical Events in Secondary Stroke Prevention: A Nationwide Cohort Study in Sweden”.

Intervention

25 papers study it10 findingsUpdated

6 new papers in 30 daysSee all 25 papers on antiplatelet therapy

At a glance

The findings reach people, from one lab or study. 5 independent labs in 5 countries.

“The largest absolute differences in mortality were associated with taking antiplatelet agents (-14.0%, 95% CrI: -31.4, 1.4%)”
Guideline-Directed Medical Therapy and Long-Term Outcomes in ISCHEMIA-EXTENDAHA Scientific Sessions 2026 abstract2026doi:10.1161/circ.154.suppl_1.5192

2 of its findings point the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 5 independent labs in 5 countries
  • 2 findings against
  • Funders: European Research Council and 7 more
  • 1 of 8 findings with company ties
  • Human trial1
  • Humans13

What did studies of antiplatelet therapy find?

5

Studies of antiplatelet therapy measured 5 outcomes, among them mortality, aneurysm growth and thrombosis.

Mortality

no changein humans1

1 study
  1. Antiplatelet therapy was not clearly linked with mortality in humans (Patients with abdominal aortic aneurysms; adjusted analysis).

    “but was also not associated with decreased mortality, thrombosis, or aneurysm growth.”

    HumansPatients with abdominal aortic aneurysms; adjusted analysisMean follow-up of 1.8 years73% malesn = 886

    Antiplatelet Therapy and Bleeding, Thrombosis, and Aneurysm Growth in Patients with Abdominal Aortic Aneurysms

    Annals of vascular surgery

Aneurysm growth

no changein humans1

1 study
  1. Antiplatelet therapy was not clearly linked with aneurysm growth in humans (Patients with abdominal aortic aneurysms).

    “but was also not associated with decreased mortality, thrombosis, or aneurysm growth.”

    HumansPatients with abdominal aortic aneurysmsAbdominal aortaMean follow-up of 1.8 years73% malesn = 886

    Antiplatelet Therapy and Bleeding, Thrombosis, and Aneurysm Growth in Patients with Abdominal Aortic Aneurysms

    Annals of vascular surgery

Thrombosis

no changein humans1

1 study
  1. Antiplatelet therapy was not clearly linked with thrombosis in humans (Patients with abdominal aortic aneurysms).

    “but was also not associated with decreased mortality, thrombosis, or aneurysm growth.”

    HumansPatients with abdominal aortic aneurysmsMean follow-up of 1.8 years73% malesn = 886

    Antiplatelet Therapy and Bleeding, Thrombosis, and Aneurysm Growth in Patients with Abdominal Aortic Aneurysms

    Annals of vascular surgery

More on Thrombosis

Bleeding

no changein humans1

1 study
  1. Antiplatelet therapy was not clearly linked with bleeding in humans (Patients with abdominal aortic aneurysms).

    “antiplatelet therapy was not observed to be associated with an increase in bleeding risk”

    HumansPatients with abdominal aortic aneurysmsMean follow-up of 1.8 years73% malesn = 886

    Antiplatelet Therapy and Bleeding, Thrombosis, and Aneurysm Growth in Patients with Abdominal Aortic Aneurysms

    Annals of vascular surgery

More on Bleeding

Dementia

no changein humans1OR 0.94

1 study
  1. Antiplatelet therapy showed no clear effect on dementia in humans (OR 0.94 [95% CI, 0.88-1.00]).

    “Antiplatelet therapy was not significantly associated with a reduced risk of cognitive impairment or dementia”

    Reviewmean trial follow-up of 5.8 yearsn = 109,860

    Antiplatelet therapy and incident cognitive impairment or dementia-a systematic review and meta-analysis of randomised clinical trials

    Age and ageing

More on Dementia

What is antiplatelet therapy linked with?

4

Studies link antiplatelet therapy with 4 measures, among them mortality, cerebral hemorrhage and dementia.

Mortality

downin humans2OR 0.8

2 studies
  1. Antiplatelet therapy is associated with mortality in humans (Chronic coronary disease) (Absolute difference -14.0 percentage points; 95% CrI -31.4 to 1.4).

    “The largest absolute differences in mortality were associated with taking antiplatelet agents (-14.0%, 95% CrI: -31.4, 1.4%)”

    HumansChronic coronary disease9 years

    Guideline-Directed Medical Therapy and Long-Term Outcomes in ISCHEMIA-EXTEND

    AHA Scientific Sessions 2026 abstract

  2. Antiplatelet therapy is linked with a lower risk of mortality in secondary multivariable analysis of nursing home residents with COVID-19 (OR 0.80, 95% CI 0.64-0.99).

    “current use of antiplatelet therapy (OR 0.80; 95% CI: 0.64-0.99) were both associated with decreased mortality.”

    Humansin secondary multivariable analysis of nursing home residents with COVID-19

    The effect of current antithrombotic therapy on mortality in nursing home residents with COVID-19: a multicentre retrospective cohort study

    Age and ageing

Cerebral hemorrhage

upin humans1

1 study
  1. Antiplatelet therapy raises the risk of cerebral hemorrhage in humans.

    “Antiplatelet therapy may increase the risk of cerebral hemorrhage”

    Review

    Brain Dock Guidelines and the Treatment of Asymptomatic Lesions: Criteria and Approaches

    Brain and nerve = Shinkei kenkyu no shinpo

More on Cerebral hemorrhage

Dementia

downin humans1

1 study
  1. Antiplatelet therapy is linked with a lower risk of dementia in newly diagnosed CSVD patients without dementia (aOR 0.15, 95% CI 0.05-0.45, p = 0.001).

    “The APT was associated with the lower overall dementia risk and the matched OR was statistically significant (aOR 0.15, 95% CI 0.05-0.45, p = 0.001)”

    Humansin newly diagnosed CSVD patients without dementian = 262

    Anti-platelet Therapy Is Associated With Lower Risk of Dementia in Patients With Cerebral Small Vessel Disease

    Frontiers in aging neuroscience

More on Dementia

Bleeding

upin humans1

1 study
  1. Antiplatelet therapy raises the risk of bleeding in humans (risk increases with aging).

    “the adverse consequences of therapy, such as risk for bleeding increases with aging as well”

    Reviewrisk increases with aging

    Modulators of platelet function in aging

    Platelets

More on Bleeding

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 2Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 2Jul 2026: 1Aug 2026: 1Sep 2026: 1Oct 2026: 3Nov 2026: 315 papers in 12 months

See all 25 papers on antiplatelet therapy